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Abstract: Background: Oesophageal adenocarcinoma (OA) is the sixth 
commonest cause of cancer death worldwide and Barrett's oesophagus (BO) 
is the most significant risk factor. We evaluated the efficacy of high-
dose esomeprazole proton pump inhibitor acid suppression (PPI) and 
aspirin in improving outcome for BE patients in the largest such 
randomized controlled trial. 
 
Methods: Patients with ≥1cm BO in UK and Canadian hospitals were 
randomized 1:1:1:1 in a 2X2 factorial design to high-dose (40mg twice-
daily) or low-dose (20mg once-daily) PPI, alone or with aspirin (UK: 
300mg/day, Canada: 325mg/day), unblinded (reporting pathologists 
blinded). The primary composite endpoint was time to all-cause mortality, 
OA, or high-grade dysplasia, analysed using accelerated failure time 
modelling adjusted for minimization factors (age, BO length, intestinal 
metaplasia). 
 
Findings: Recruited patients (N=2557) were followed for 8·9 years 
(median; interquartile range 8·2-9·8), collecting 20,095 follow-up years 
and 99·9% of planned data. There were 313 primary events. High-dose PPI 
was superior to low-dose PPI (p=0·037, N=2535, time ratio (TR)=1·27, 
95%CI=1·01-1·58). Aspirin was not significantly better than no aspirin 
(p=0·068, N=2280, TR=1·24, 95%CI=0·98-1·57). If patients using NSAIDs 
were censored at time of first use, aspirin was significantly better 
(p=0·043, N=2,236, TR=1·29 95%CI=1·01-1·66). Combining high-dose PPI with 
aspirin had the strongest effect compared with low-dose PPI without 
aspirin (p=0·007, TR=1·59, 95%CI=1·14-2·23). NNT for PPI and aspirin 
benefit is 34 and 43, respectively. Only 1·0% of participants reported 
study-treatment-related serious adverse events. 
 
Interpretation: High-dose PPI and aspirin chemoprevention therapy, 
especially in combination, significantly and safely improve outcome in BO 
patients.   
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Abstract  99 
Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer 100 
death worldwide and Barrett’s oesophagus (BO) is the most significant risk factor. We 101 
evaluated the efficacy of high-dose esomeprazole proton pump inhibitor acid suppression 102 
(PPI) and aspirin in improving outcome for BO patients in the largest such randomized 103 
controlled trial.  104 
Methods: Patients with ≥1cm BO in UK and Canadian hospitals were randomized 1:1:1:1 105 
using a computer-generated schedule held in a central trials unit in a 2X2 factorial design to 106 
high-dose (40mg twice-daily) or low-dose (20mg once-daily) PPI, alone or with aspirin (UK: 107 
300mg/day, Canada: 325mg/day), unblinded (reporting pathologists blinded). The primary 108 
composite endpoint was time to all-cause mortality, OA, or high-grade dysplasia, analysed 109 
using accelerated failure time modelling adjusted for minimization factors (age, BO length, 110 
intestinal metaplasia). 111 
Findings: Recruited patients (N=2557) were followed for 8·9 years (median; interquartile 112 
range 8·2–9·8), collecting 20,095 follow-up years and 99·9% of planned data. There were 113 
313 primary events. High-dose PPI was superior to low-dose PPI (p=0·037, N=1265 (low 114 
dose), N=1270 (high dose), time ratio (TR)=1·27, 95%CI=1·01–1·58). Aspirin was not 115 
significantly better than no aspirin (p=0·068, N=1142 (no aspirin), N = 1138 (aspirin), 116 
TR=1·24, 95%CI=0·98–1·57). If patients using NSAIDs were censored at time of first use, 117 
aspirin was significantly better than no Aspirin (p=0·043, N=2,236, TR=1·29 95%CI=1·01–118 
1·66). Combining high-dose PPI with aspirin had the strongest effect compared with low-119 
dose PPI without aspirin (p=0·0068, TR=1·59, 95%CI=1·14–2·23). NNT for PPI and aspirin 120 
benefit is 34 and 43, respectively. Only 1·0% (28) of participants reported study-treatment-121 
related serious adverse events. 122 
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Interpretation: High-dose PPI and aspirin chemoprevention therapy, especially in 123 
combination, significantly and safely improve outcome in BO patients.  124 
Funding: Cancer Research UK 125 
EudraCT 2004-003836-77 126 
New Findings: 127 
High dose proton pump inhibitor therapy (80 mg Esomeprazole/day) reduced the 128 
combination of all-cause mortality, oesophageal adenocarcinoma and high-grade dysplasia in 129 
Barrett’s oesophagus patients compared to low dose [20 mg/day] (number needed to treat 130 
(NNT) = 34 over 9 years, and Hazard ratio 0.80) 131 
Aspirin also had an effect on these endpoints in BO (NNT = 43 over 9 yrs, Hazard ratio 0.78) 132 
Both treatments appear to have an additive effect 133 
Significant side effects were rare<1%. 134 
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Background  135 
Oesophageal adenocarcinoma (OA) incidence has increased dramatically in North America 136 
and Europe over the last 40 years.1 The incidence may be plateauing, although areas such as 137 
Hawaii are still seeing 8% annual increases.1 There are over 52,000 cases of OA worldwide 138 
annually and 5-year survival is <10% when detected through symptoms. Increasing incidence 139 
of OA is probably related to the rise in gastro-oesophageal reflux disease in Western 140 
populations.2-5 141 
Gastro-oesophageal reflux is one of the main risk factors for Barrett’s oesophagus (BO), 142 
where a portion of the oesophagus usually lined with squamous epithelium undergoes 143 
metaplastic change to columnar mucosa. BO is a complex, genetically predisposed, pre-144 
malignant condition,6 affecting 2% of the adult population and can progress to 145 
adenocarcinoma, following the sequence oesophagitis-metaplasia-dysplasia-146 
adenocarcinoma.7, 8 Current strategies for improving OA survival include BO surveillance to 147 
detect early stage cancer. This has modestly improved outlook of OA, prolonging median 148 
survival from 6 to 10 months.9 Strategies to prevent progression to OA could give more 149 
dramatic gains. For example, colorectal cancer screening has proved successful with 150 
approximately 33% of colorectal cancer deaths now prevented by early detection versus 66% 151 
by polyp removal (i.e. prevention).10 152 
Early detection of BO is confined to research settings, however there are promising 153 
chemoprevention strategies. Proton pump inhibitors (PPIs) effectively reduce acid reflux, 154 
thought to be one of the main drivers for BO. After BO development, PPIs down-regulate 155 
cylogogenase-2 expression, which may protect against neoplastic progression.11 156 
Observational data have suggested that BO patients taking PPIs have reduced neoplastic 157 
progression,12 but this is low quality, controversial evidence.13 A recent systematic review 158 
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supports the view that more powerful acid suppression may reduce risk of neoplasia.14 159 
Esomeprazole is the commonest PPI used in the USA, allowing healing of oesophagitis 160 
without promoting clonal expansion of Barrett’s.15 Observational data suggest that aspirin use 161 
is associated with reduced risk of OA,16-19 but this is not a universal finding.20 Finally, 162 
although BO is a major risk factor for OA, only a minority of BO patients die from OA; most 163 
die from cardiovascular disease or chest infections.21 Preventative strategies should ideally 164 
impact overall mortality. 165 
No randomised trial has evaluated PPI or aspirin for improving outcome including preventing 166 
neoplastic progression in BO patients. We evaluated the efficacy of these agents in the 167 
Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT). 168 
AspECT is a phase III, randomised prospective factorial study of chemoprevention by aspirin 169 
and esomeprazole in patients with BO, assessing the efficacy and safety of these interventions 170 
in reducing all-cause mortality, OA, and high-grade dysplasia (HGD). 171 
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Methods  172 
Participants. Participants were recruited by gastroenterologists and upper gastrointestinal 173 
surgeons through hospital clinics and endoscopy lists, including new and existing BO 174 
diagnoses. There were 84 centres across England, Scotland, Wales, and Northern Ireland, and 175 
1 in McMaster Health Sciences Centre, Canada. Participants ≥18 years old with globally 176 
accepted criteria for BO, at least 1 cm of histologically proven columnar-lined oesophagus,22 177 
were eligible. Exclusion criteria included pre-existing OA, HGD, or taking NSAIDs at 178 
baseline. Detailed inclusion and exclusion criteria are given in Supplementary Table 1. As 179 
women with BO have a lower risk of OA than men22, we limited recruitment of women to 180 
approximately 500.  181 
Randomisation and masking 182 
 Participants were randomized using a computer-generated schedule administered by a central 183 
trials unit to maintain allocation concealment. Some had contra-indications to or were already 184 
taking Aspirin for cardiovascular secondary prevention. We allowed these participants to 185 
enter PPI randomisation only. We therefore expected more participants in the PPI than the 186 
aspirin randomisation.  187 
Randomisation was by minimisation with a random element of 0·8. The minimisation factors 188 
chosen were possible risk factors for the development of HGD, adenocarcinoma, and death: 189 
Length of BO: tongue, <2cm, ≥2cm and ≤3cm, >3cm and ≤8cm, >8cm 190 
Age in years: 18-49, 50-59, 60-69, ≥70 191 
Intestinal metaplasia: yes, no 192 
Using minimisation with the same variables, women and men were randomised separately, as 193 
were those only taking part in the PPI randomization. Treatment was not blinded. 194 
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Participants were randomised 1:1:1:1 in a 2X2 factorial design to esomeprazole at either high 195 
(40mg twice-daily) or low (20mg once-daily) dose, alone or in combination with aspirin (one 196 
standard-dose tablet, UK: 300mg/day, Canada: 325mg/day). 197 
Trial procedures and interventions. 198 
At annual follow-up, all patients were asked about hospital admissions and medical records 199 
checked for Serious Adverse Events. Follow-up in years 1,3,5,7,9 was by face to face or 200 
telephone interview, and in years 2,4,6,8,10 patients underwent endoscopy. All centres were 201 
trained and centrally monitored for endoscopy and pathology quality: strict adherence was 202 
essential for both site set up and for individual participant recruitment, with trial office 203 
validation of criteria on faxed/scanned endoscopy and pathology forms before enrolment. 204 
Intestinal metaplasia (IM) was present in 2266 (89%) at initial endoscopy, the remainder a 205 
mosaic of gastric metaplasia, increasing to 100% with IM on subsequent endoscopies.23, 24 206 
Trial endoscopists received training in use of C and M endoscopy criteria with central 207 
monitoring of images and videos.25 Standardised pathology criteria for reporting BO biopsies 208 
were developed, with training overseen by a central pathology panel as published.24 At each 209 
endoscopy, four-quadrant BO biopsies every 2cm, with separate targeted biopsy of any 210 
macroscopic abnormalities, were fixed in buffered formalin, transported to the pathology lab, 211 
processed within 24 hours, embedded in wax, cut, stained with H&E and assessed by local 212 
gastrointestinal pathologists. All cases of dysplasia or cancer were double reviewed by 213 
regional pathology teams, with arbitration by central pathology panel if uncertainty. Local 214 
and central pathologists were blinded to treatment allocation. Many cases of dysplasia/cancer 215 
and a random 10% of all non-dysplastic cases were reviewed by a central expert pathology 216 
panel. Reports were seen by the local clinical team, decisions actioned and then faxed to the 217 
central trial office for validation/checking.  All centres in all countries adhered to the same 218 
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protocol except for the dose of aspirin which was 300mg per day in the UK and 325 mg per 219 
day in Canada. 220 
Outcomes. The co-primary aims were efficacy of high- versus low-dose PPI, and efficacy of 221 
aspirin versus no aspirin. The primary composite endpoint was time to the first of all-cause 222 
mortality, OA, or HGD. Secondary aims (which were not fully powered) included each 223 
treatment’s effect on time to each of all-cause mortality, OA, HGD, cause-specific mortality 224 
and effect of gender.  225 
Statistics and sample size power calculations. We used intention-to-treat analysis, 226 
including all randomised participants who did not rescind consent, analysing them in the 227 
treatment groups they were randomised to. We checked the significance of the treatment 228 
interaction term by first adding an interaction term to a primary model before using ‘at the 229 
margins’ and ‘within table’ results to produce an interaction ratio. Whilst recognising that the 230 
power was low for this interaction comparison, the appropriateness of an analysis using the 231 
factorial design was concluded. 232 
 233 
All analyses used accelerated failure time (AFT) modelling, adjusting for minimisation 234 
factors. An accelerated failure time model was interpreted in terms of the speed of time to an 235 
event using time ratio (TR). TR>1 for the composite endpoint implied that the treatment 236 
prolonged time to an event. AFT was used due to the intuitive nature of the time ratio which 237 
models survival time, it’s benefit of reporting results as a delay in event over the entire trial 238 
period compared to the hazard ratio result which is interpreted as risk of an event at any one 239 
given time. Cox proportional hazards survival analyses, and where appropriate, Cox 240 
competing risks survival analyses were also performed on all comparisons to allow for 241 
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comparison with other research. Before the use of both AFT and Cox survival models, the 242 
assumption of proportional hazards was tested using Schoenfeld tests and plots of residuals. 243 
Median follow-up was calculated using a reverse Kaplan-Meier method.26 244 
The trial aimed to recruit 5000 participants (1250 in each intervention group), assuming no 245 
interaction between the effects of aspirin and PPI interventions, an exponential time-to-246 
composite-event with a constant event rate of 0·76% per year, a composite event hazard ratio 247 
of 1·4, recruiting over 2 years, follow-up for 8 years, 10% loss to follow-up, 20% non-248 
compliance with medication, 80% power, and a 2-sided test at 5% significance. In October 249 
2008, at the TSC, DSMC and funder’s request, sample size was amended to allow emerging 250 
external data to be incorporated into the statistical calculations, namely published evidence 251 
showing an expected higher effect of aspirin (the raw data was available pre-publication with 252 
permission as JJ was a co-author),27 higher conversion rate to cancer and the realisation that 253 
the initial composite event rate was too cautious.21 It was agreed to be more efficient and cost 254 
effective to decrease the recruitment target but to extend follow-up to 10 years to allow more 255 
events to accrue in the ageing trial population.  The new sample size of 2224 participants 256 
(196 events) was based on the above calculations but changed the constant event rate for the 257 
composite event (death, cancer or HGD) to a conservative 1% per year, the composite event 258 
hazard ratio to 1·5, recruitment to 3 years, follow-up for a maximum of 10 years, and 259 
removed the adjustment for medication compliance. With TSC and DSMC agreement, the 260 
funder permitted the trial to recruit until the end of February 2009 or 2224 participants, 261 
whichever was later. We recruited 2557 patients, 15% over the minimum power needed.  262 
The primary aim was analysed and presented confidentially to the trial’s data safety 263 
monitoring committee as specified in the protocol after 2 and 4 years of follow-up as interim 264 
analyses considering p<0·001 as significant. The committee recommended trial continuation 265 
and neither interim analysis was disseminated further. 266 
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The 2x2 factorial design provides two co-primary comparisons, high dose PPI compared to 267 
low dose PPI and aspirin compared to no aspirin. Secondary analyses of each element of the 268 
composite endpoint (HGD, OA, all-cause mortality) were evaluated in the same way as the 269 
primary comparisons using both AFT and Cox survival analyses. A per protocol population 270 
was defined based on treatment and trial compliance detailed in supplementary tables 17 and 271 
18, with all analyses repeated as per primary methods. There were no missing data present in 272 
variables used in the primary and secondary analyses. There was no adjustment made to any 273 
analysis for multiple testing. Number needed to treat and number needed to harm were 274 
calculated using 1/absolute risk difference of primary event or adverse event respectively. 275 
Safety data are presented in descriptive form with no statistical analysis performed. All 276 
analyses were performed using StataCorp Version 15.0. 277 
 278 
The funder had no role in data collection, analysis, interpretation, writing and decision to 279 
submit. The authors who had access to all the data were the Trial Management Group: John 280 
de Caestecker, Janusz Jankowski (JJ), Yeng Ang, Stephen Attwood, Sharon Love, Rebecca 281 
Harrison, Danielle Morris, Hugh Barr, Scott Sanders, Peter Watson, Adelyn Wise, Claire 282 
Brooks, Gavin Reilly, Pradeep Bhandari and Paul Moayyedi. Those who took a decision to 283 
submit were Janusz Jankowski, Paul Moayyedi, Sharon Love, Gavin Reilly, John de 284 
Caestecker, Hugh Barr, Scott Sanders, Rebecca Harrison, Claire Brooks. 285 
 286 
Ethics. AspECT was approved by the Main Research Ethics Committee in the UK (REC 287 
reference: P1/04/Q0603/1) and by the Hamilton Integrated Research Ethics Board in Canada 288 
(reference:06-2731). All participants provided fully informed consent.289 
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Results  290 
Recruitment 291 
We recruited 2557 BO patients from March 2005 to March 2009 and followed them for 8·9 292 
years (median; interquartile range 8·2–9·8), collecting 20,095 patient-years of data. There 293 
were 313 primary endpoint events. Follow-up was completed by March 2017 (see 294 
CONSORT diagram in Figure 1 and supplementary table 2). Participants’ baseline 295 
characteristics are in Table 1 and supplementary table 2 and compliance with medication in 296 
Supplementary Figure 1. The trial achieved a data return rate of 99·9%, with only one case 297 
report form outstanding out of 66,200. 298 
Treatment interaction 299 
The PPI/aspirin interaction term was not significant, leading to separate analysis of the PPI 300 
and aspirin comparisons (p=0·2807, N=2280, TR=1·30, 95% CI=0·81–2·09). Supplementary 301 
Table 4 gives the event rates in each arm.  302 
Primary analysis for PPI 303 
The primary analysis for PPI (Figure 2(a)) found that high-dose was significantly more 304 
effective than low-dose (p=0·0375, N=2535, TR=1·27, 95% CI=1·01–1·58). High-dose PPI 305 
significantly lengthened the time to reach endpoints, indicating that high-dose PPI delays 306 
death, cancer, and dysplasia. If the expected time to the composite event whilst taking low-307 
dose PPI was 8 years, taking high-dose would increase this to 10·2 years (95% CI=8·1–12·6). 308 
Primary analysis for aspirin 309 
The primary analysis for aspirin (Figure 2(b)) was not significant (p=0·0683, N=2280, 310 
TR=1·24, 95% CI=0·98–1·57). UK sites also collected information on non-steroidal anti-311 
inflammatory drug (NSAID) use. As specified in the statistical analysis plan, we included 312 
only UK participants and censored follow-up when a participant began taking NSAIDs. We 313 
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could then compare aspirin use with no aspirin, in the absence of NSAIDs. Aspirin had a 314 
significant effect on the composite endpoint when not combined with NSAIDs (p=0·0431, 315 
N=2,236, TR=1·29 95% CI=1·01–1·66). 316 
Primary analysis for combined therapy 317 
The beneficial effects of PPI and aspirin appeared additive when taken in combination 318 
(Figure 2(c)). Combining aspirin with high-dose PPI had the strongest effect, compared with 319 
low-dose PPI and no aspirin (p=0·0068, TR=1·59, 95% CI=1·14–2·23). We also compared 320 
the effect of aspirin combined with high-dose PPI to high-dose PPI alone, with a TR to 321 
endpoint of 1·38 (95% CI 0·98-1·94; p=0·0680), suggesting primary event delay of an 322 
additional 38% in high-dose PPI and aspirin compared to high-dose PPI alone. The 323 
confidence interval suggests support for this effect, though not statistically significant as the 324 
trial was not powered for this analysis (high-dose PPI & aspirin combination: 52 events vs. 325 
high-dose PPI: 87). 326 
Secondary analyses  327 
Table 2 gives the results of the secondary analyses. Aspirin appears protective against HGD 328 
(the precursor lesion to OA) showing marginal significance (p=0·0526, TR=1·51, 95% 329 
CI=1·00–2·29).  330 
We designed the trial to use accelerated failure time modelling and give TRs, as these are 331 
easier to interpret than other estimates. Supplementary Table 5 gives the results from a Cox 332 
model in hazard ratios to allow comparison with other studies. We also supply Kaplan Meier 333 
plots for effects on all-cause mortality and HGD/OA separately (Supplementary figure 2) 334 
respectively  for Aspirin vs no Aspirin (Figures 2a and 2b) and high dose vs low dose PPI 335 
(Figures 2c and 2d). 336 
16 
 
 
We calculated the number needed to treat (NNT) to prevent HGD, adenocarcinoma or death 337 
with both primary therapies (aspirin v no aspirin, low-dose v high-dose PPI). In the aspirin 338 
comparison, we estimated that on average 43 patients would need to be treated with aspirin to 339 
prevent one event (95% CI:20-250). In the PPI comparison, we calculated an NNT of 34 for 340 
high-dose PPI, i.e. 34 patients needed to be treated with high-dose instead of low-dose PPI to 341 
prevent one event (95% CI:18-333). 342 
Long-term safety of aspirin and PPI therapy 343 
There were 1132 serious adverse events (SAEs) in 718 participants, of which 65 SAEs in 61 344 
participants were considered related to one or both treatments. Those with Common 345 
Terminology Criteria for Adverse Events (CTCAE) grade 3–5 are shown in Table 3. Only 346 
1% of participants had an SAE of CTCAE grade 3–5 related to a study treatment (Table 3; 347 
Supplementary Tables 6 and 7). Sixty-four episodes of haemorrhage were recorded in 59 trial 348 
patients, with more events in the aspirin arms, but <1% of all patients experienced a CTCAE 349 
grade 3–5 bleed. There were 7 grade  3–5 gastrointestinal bleeds (Supplementary Tables 8 350 
and 9). Total SAEs for high-dose PPI was 303 (in 704 patients) versus 274 (in 571 patients) 351 
for high-dose PPI & aspirin combination with little difference between them. 352 
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Discussion  353 
This is the first randomised trial evaluating PPI and aspirin chemoprevention in BO and is the 354 
largest randomised trial ever conducted in BO, with 20,095 participant-years of follow-up in 355 
2557 patients. We have shown that high-dose PPI use protects against a composite of all-356 
cause mortality, OA, and HGD. Aspirin use also protects against the composite endpoint, 357 
when patient follow-up is censored at start of concomitant NSAID use. The data suggest the 358 
two therapies are additive, as the group who took both high-dose PPI and aspirin had the 359 
strongest benefit. High-dose PPI appeared to confer the single biggest effect, and 360 
combination with aspirin added another 38% benefit. Both agents were well-tolerated with 361 
few serious events. It seems likely that the use of aspirin and PPI would improve survival in 362 
BO if given for at least 9 years. 363 
This study has several limitations. As we assessed only a small fraction of BO patients in 364 
predominantly white populations in five countries, our results may not be fully generalisable 365 
to all ethnic populations. However, BO is currently predominantly seen in Caucasians 366 
worldwide. We also limited the study to only approximately 500 women. Although our drug 367 
treatment was not blinded, the outcomes of OA and all-cause mortality are objective and 368 
unlikely to be biased by lack of blinding. A masked pathology panel with double reporting 369 
was used to minimise bias in evaluating HGD and OA.  Two hundred and fifty-five patients 370 
took part only in the PPI randomisation due to being aspirin intolerant or not able to stop 371 
taking aspirin so this is a more generalisable group reflecting the situation in the population at 372 
large; since these were randomised between low-dose and high-dose PPI we would not 373 
expect an effect on the PPI comparison. The 95% confidence intervals are wide and the lower 374 
limit close to unity when each drug is evaluated individually, suggesting that the results are 375 
not robust. As aspirin and NSAIDs are available over the counter, participants could have 376 
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taken these drugs without reporting to the investigator. This would have biased the results 377 
towards the null hypothesis and therefore would only underestimate aspirin’s efficacy. 378 
Our data are supported by a meta-analysis of selected randomized controlled cardiovascular 379 
prevention trials evaluating aspirin versus placebo, which found that OA was reduced.17 380 
There are concerns about these data,18 and the studies in the meta-analysis did not evaluate 381 
patients with BO. Nevertheless, our data add support to the possibility that aspirin prevents 382 
OA. Although a systematic review of observational studies suggested that PPI therapy 383 
reduces the risk of OA and HGD,14 these results are liable to bias or confounding inherent in 384 
observational study design.  385 
Our results with PPI are supported at the physiological level by studies showing that twice-386 
daily PPI produces more effective suppression of acid reflux than once-daily dosing and more 387 
provocatively that high-dose PPI also allows preferential healing of BO segments into 388 
squamous epithelium.15, 28 There is little data in the literature on combining PPI and aspirin to 389 
prevent neoplastic progression of BO, and this is the first randomised trial data to suggest the 390 
drugs may have additive effects.  391 
Our results have implications for clinical practice. Current Barrett’s and reflux oesophagitis 392 
guidelines in the UK and North America propose that the ‘lowest effective dose to minimise 393 
reflux symptoms should be used’.22, 29 Our data indicate that high-dose PPI (40 mg twice-394 
daily) is better than low-dose (20 mg once-daily) for BO patients in delaying death, cancer, 395 
and dysplasia. Our data also suggest that 300/325 mg daily aspirin is effective in reducing the 396 
composite endpoint, although we do not know if this is the optimal dose. The NNT for high-397 
dose PPI and aspirin is 34 and 43 respectively to prevent one event. Combining high-dose 398 
PPI and aspirin appears more effective in reducing the composite endpoint than either 399 
treatment alone. The combination appears safe, with only 1% of participants reporting an 400 
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SAE of CTCAE grade 3–5 with little increase when adding aspirin to high-dose PPI. Current 401 
guidelines do not address the possibility of giving aspirin to reduce neoplastic progression in 402 
BO; our results suggest review of existing guidelines is warranted.  403 
Several questions remain unanswered. How long must patients take PPI and aspirin combined 404 
to benefit from chemopreventative effects on oesophageal stem cells? We know that before 5 405 
years neither therapy had a significant benefit,19 but that after 8·9 years of follow-up, the 406 
effect was significant. We also do not yet know the pharmacogenomics of who responds best 407 
to either or both therapies.8 This work is now ongoing.30 These data also raise the possibility 408 
that all patients needing long-term PPI to control reflux symptoms might benefit from aspirin 409 
co-prescribed with acid suppression. The PPI could reduce the upper gastrointestinal bleeding 410 
associated with aspirin whilst the benefits of aspirin remain. This hypothesis should be 411 
evaluated in large population-based trials. 412 
This is the largest randomised controlled chemoprevention trial of BO. We have shown that 413 
high-dose PPI and aspirin chemoprevention therapy, especially in combination, significantly 414 
and safely reduce combined rates of HGD, OA and all-cause mortality.  415 
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Table 1: Baseline characteristics of AspECT trial participants, stratified by treatment 
group 
Variable at baseline Low PPI 
N=1265 
High PPI 
N=1270  
No aspirin 
N=1142 
Aspirin 
N=1138 
Length of Barrett’s metaplasia at randomization 
(strata for minimization and median (IQR), cm) 
N=2413* N=2159 
4 (3 , 6) 4 (2 , 6) 4 (2 , 6) 4 (3 ,6) 
Length of Barrett’s (stratification group)  
 
     <2 cm 
     2-3 cm 
     3-8 cm 
     >8 cm 
    Tongues 
N=2535 N=2280 
 
123 (10%) 
434 (34%) 
538 (43%) 
130 (10%) 
40 (3%) 
 
124 (10%) 
435 (34%) 
539 (42%) 
129 (10%) 
43 (3%) 
 
108 (9%) 
398 (35%) 
491 (43%) 
117 (10%) 
28 (3%) 
 
109 (10%) 
395 (35%) 
493 (43%) 
118 (10%) 
23 (2%) 
Age  
(strata for minimization, median (IQR),years) 
N=2535 N=2280 
59 (51 , 65) 59 (51 , 65) 58 (50 , 64) 58 (50 , 65) 
Age (stratification grouping) 
 
     <50 years 
     50-60 years 
     60-70 years 
     >70 years 
N=2535 N=2280 
 
283 (22%) 
388 (31%) 
447 (35%) 
147 (12%) 
 
280 (22%) 
390 (31%) 
445 (35%) 
155 (12%) 
 
269 (24%) 
365 (32%) 
386 (34%) 
122 (10%) 
 
272 (24%) 
358 (31%) 
388 (34%) 
122 (11%) 
 
Intestinal metaplasia 
      Yes 
       No 
N=2535 N=2280 
 
1,130 (89%) 
134 (11%) 
 
1,136 (90%) 
134 (10%) 
 
1,042 (91%) 
100 (9%) 
 
1,035 (91%) 
103 (9%) 
 
Sex 
      Male 
       Female 
N=2535 N=2280 
 
1012 (80%) 
253 (20%) 
 
1010 (80%) 
260 (20%) 
 
900 (79%) 
242 (21%) 
 
896 (79%) 
242 (21%) 
* we required the length of Barrett’s stratification group for randomization. The actual length of Barrett’s was 
collected on the baseline data form and was missing for 122 patients. 
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Figure 2(a) 
 
Figure 2(b) 
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Figure 2(c) 
  
 
Figure 2: Survival curves comparing patients on (a) high-dose PPI and low-dose PPI, (b) 
aspirin and no aspirin, and (c) all four treatment groups 
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Supplementary table 2: Reasons for non-enrolment in AspECT of patients meeting 
inclusion criteria 
Exclusion Reason Number of Patients 
ALCOHOLIC 9 
DECEASED 18 
MISUNDERSTANDING OF TRIAL 6 
NO RESPONSE 132 
NO SURVEILLANCE 28 
NOT MOBILE 6 
ON HOLIDAY 1 
ON TRIAL 22 
OPTED FOR SURGERY 13 
PRISONER 1 
QUOTA REACHED 3 
RELOCATING 26 
SELF DISCHARGED 1 
UNABLE TO COMPLETE FOLLOW UP 17 
UNABLE TO GIVE CONSENT 8 
UNSPECIFIED INELIGIBILITY 114 
UNWILLING TO ADOPT TRIAL 
TREATMENT 
13 
OTHER 81 
TOTAL 499 
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Supplementary Table 3: Baseline characteristics by treatment comparison for variables 
only asked of patients recruited in the first 2 years of recruitment 
Variable at baseline Low PPI 
N=1247 
High PPI 
N=1244  
No Aspirin 
N=1120 
Aspirin 
N=1116 
BMI (kg/m2) 
  
median(IQR) 
N=1254 N=1039 
27 (25 , 30) 27 (25 , 30) 27 (25 , 30) 27 (25 , 30) 
Duration of Barrett’s pre randomisation (years) 
    Median (IQR) 
N=2373 N=2123 
2·5 (0·4 , 5·7) 2·4 (0·4 , 6·1) 2·5 (0·4 , 5·9) 2·3 (0·4 , 5·8) 
Alcohol use  
 
     None 
      Some 
 
(For some group, median (IQR), units per week) 
 
N=1033 N=1032 
 
131 (25%) 
385 (75%) 
 
10 (4 , 20) 
 
125 (24%) 
392 (76%) 
 
10 (4 , 20) 
 
131 (25%) 
386 (75%) 
 
10 (5 , 20) 
 
125 (24%) 
390 (76%) 
 
10 (4 , 20) 
Smoker  
      Never 
      Ex 
      Current 
N=1031 N=1031 
 
223 (43%) 
209 (41%) 
84 (16%) 
 
223 (43%) 
201 (39%) 
91 (18%) 
 
223 (43%) 
202 (39%) 
94 (18%) 
 
222 (43%) 
208 (41%) 
81 (16%) 
Myocardial infarction   
 
      Yes 
      No 
N=1393 N=1143 
 
13 (2%) 
688 (98%) 
 
13 (2 %) 
679 (98%) 
 
1 (0·2%) 
573 (99·8%) 
 
1 (0·2%) 
568 (99·8%) 
Angina 
      
      Yes 
      No 
N=1394 N=1143 
 
24 (3%) 
677 (97%) 
 
26 (4%) 
667 (96%) 
 
3 (0·5%) 
572 (99·5%) 
 
6 (1%) 
562 (99%) 
Coronary Intervention 
 
      Yes 
      No 
N=1394 N=1143 
 
13 (2%) 
688 (98%)  
 
12 (2%) 
681 (98%) 
 
0 
575 (100%) 
 
2 (0·4%) 
566 (99·6%) 
Stenosis 
 
      Yes 
      No 
N=1393 N=1141 
 
2 (0·3%) 
700 (99·7%) 
 
5 (0·7%) 
686 (99·3%) 
 
0  
575 (100%) 
 
1 (0·2%) 
565 (99·8%) 
Cardiac catheterisation 
 
      Yes 
      No 
N=1392 N=1140 
 
13 (2%) 
688 (98%) 
 
15 (2%) 
676 (98%) 
 
2 (0·4%) 
572 (99·6%) 
 
2 (0·4%) 
564 (99·6) 
Cerebrovascular 
 
      Yes 
      No 
N=1392 N=1140 
 
2 (0·3%) 
699 (99·7%) 
 
8 (1%) 
683 (99%) 
 
1 (0·2%) 
573 (99·8%) 
 
3 (0·5%) 
564 (99·5%) 
TIA 
 
      Yes 
      No 
N=1390 N=1139 
 
2 (0·3%) 
696 (99·7%) 
 
5 (0·7%) 
687 (99·3%) 
 
0 
572 (100%) 
 
2 (0·4%) 
565 (99·6%) 
Peripheral Vascular Disease 
 
      Yes 
      No 
N=1378 N=1131 
 
 
6 (1%) 
686 (99%) 
 
 
9 (1%) 
677 (99%) 
 
 
3 (0·5%) 
565 (99·5%) 
 
 
5 (1%) 
558 (99%) 
Diabetes 
 
      Yes 
      No 
N=1032 N=1031 
 
18 (3%) 
499 (97%) 
 
13 (3%) 
502 (97%) 
 
13 (3%) 
503 (97%) 
 
18 (4%) 
497 (96%) 
Hypertension 
 
      Yes 
      No 
N=1032 N=1031 
 
116 (23%) 
399 (77%) 
 
129 (25%) 
288 (75%) 
 
122 (24%) 
393 (76%) 
 
123 (24%) 
393 (76%) 
Hyperlipidaemia 
 
       Yes 
        No 
        Unknown 
N=1034 N=1033 
 
47 (9%) 
287 (56%) 
182 (35%) 
 
43 (8%) 
262 (51%) 
213 (41%) 
 
46 (9%) 
275 (53%) 
198 (38%) 
 
44 (9%) 
273 (53%) 
197 (38%) 
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Supplementary Figure 1: Participant compliance with (a) PPI and (b) aspirin 
medication, by treatment group 
Figure 1(a): PPI compliance 
 
 
Figure 1(b): Aspirin compliance 
 
 
PPI and aspirin dose changes shown above were pre-specified in the protocol and permitted.  
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Supplementary table 4: Details of primary outcome breakdown by treatment arm 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
PPI 
  High-dose Low-dose 
 
A
sp
ir
in
 
Yes 52 / 572 = 0·091 
All-cause mortality                              25 (48%) 
Oesophageal adenocarcinoma             12 (23%) 
High-grade dysphasia                          15 (29%) 
 
75 / 566 = 0·133 
All-cause mortality                              37 (50%) 
Oesophageal adenocarcinoma             19 (25%) 
High-grade dysphasia                        19 (25%) 
No  
87 / 698 = 0·125 
All-cause mortality                              43 (49%) 
Oesophageal adenocarcinoma             19 (22%) 
High-grade dysphasia                          25 (29%) 
 
99 / 699 = 0·142 
All-cause mortality                              50 (51%) 
Oesophageal adenocarcinoma             11 (11%) 
High-grade dysphasia                          38 (38%) 
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Supplementary Table 6: Serious adverse events and serious adverse reactions by 
Common Terminology Criteria for Adverse Events grade 
 CTCAE Grade  
All serious adverse events by system  1 2 3 4 5 Total 
Blood and lymphatic system disorders 5 3 5 2 0 15 
Cardiac disorders 9 36 77 24 12 158 
Ear and labyrinth disorders 1 1 3 0 0 5 
Endocrine disorders 0 0 2 0 0 2 
Eye disorders 0 3 4 0 0 7 
Gastrointestinal disorders 24 69 50 6 2 151 
General disorders and administration site conditions 11 15 18 0 0 44 
Hepatobiliary disorders 2 15 19 2 5 43 
Immune system disorders 1 1 2 1 0 5 
Infections and infestations 7 57 109 9 5 187 
Injury, poisoning and procedural complications 7 23 41 4 6 81 
Investigations 1 0 0 3 0 4 
Metabolism and nutrition disorders 3 6 5 4 0 18 
Musculoskeletal and connective tissue disorders 3 12 10 1 0 26 
Neoplasms benign, malignant and unspecified 
(including cysts and polyps) 
3 16 41 22 45 127 
Nervous system disorders 16 41 37 13 7 114 
Psychiatric disorders 1 3 6 4 2 16 
Renal and urinary disorders 5 14 16 1 0 36 
Respiratory, thoracic and mediastinal disorders 5 18 12 3 0 38 
Skin and subcutaneous tissue disorders 0 0 1 0 0 1 
Vascular disorders 1 5 19 6 4 35 
Total 105 338 477 105 88 1113* 
*Nineteen serious adverse events are missing a CTCAE grade. 
       
Serious adverse reactions       
Related to aspirin 9 19 12 2 1 43* 
Related to esomeprazole 2 4 10 2 1 19 
Related to both aspirin and esomeprazole 0 2 0 0 0 2 
Total 11 25 22 4 2 64* 
*One serious adverse reaction is missing a CTCAE grade 
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CTCAE: Common Terminology Criteria for Adverse Events. 
Supplementary Table 7: Total SAEs by treatment arm 
 Treatment Arm  
SAE System / Category Low PPI High PPI Low PPI 
Asp 
High PPI 
Asp 
Total 
Blood and lymphatic system disorders 2 5 9 1 17 
Cardiac disorders 37 50 38 35 160 
Ear and labyrinth disorders 0 1 1 3 5 
Endocrine disorders 1 0 0 1 2 
Eye disorders 0 2 1 4 7 
Gastrointestinal disorders 39 34 41 38 152 
General disorders and administration site conditions 8 16 8 15 47 
Hepatobiliary disorders 10 8 14 11 43 
Immune system disorders 1 3 0 1 5 
Infections and infestations 49 46 35 58 188 
Injury, poisoning and procedural complications 18 26 24 14 82 
Investigations 1 1 1 1 4 
Metabolism and nutrition disorders 5 8 1 4 18 
Musculoskeletal and connective tissue disorders 9 2 6 9 26 
Neoplasms benign, malignant and unspecified (incl cysts and 
polyps) 
38 41 28 27 134 
Nervous system disorders 30 27 31 26 114 
Pregnancy, puerperium and perinatal conditions 1 0 0 0 1 
Psychiatric disorders 4 6 1 5 16 
Renal and urinary disorders 14 9 5 8 36 
Respiratory, thoracic and mediastinal disorders 9 6 18 6 39 
Skin and subcutaneous tissue disorders 0 1 0 0 1 
Vascular disorders 7 11 10 7 35 
OVERALL TOTAL 283 303 272 274 1132 
 
 
 
 
40 
 
 
Supplementary Table 8: Gastrointestinal and non-gastrointestinal bleeds classified as serious adverse 
events in each treatment group. 
Presented as total bleeds in each category (grade 3–5 bleeds in that category). 
CTCAE: Common Terminology Criteria for Adverse Events
 Low or high PPI  Aspirin or no aspirin  
Serious adverse events by system / category Low PPI High PPI Aspirin No aspirin 
 
Gastrointestinal bleeds (CTCAE grade 3–5 bleeds) 
Colonic hemorrhage 1 (0) 0 (0) 0 (0) 1 (0) 
Duodenal hemorrhage 0 (0) 2 (1) 2 (1) 0 (0) 
Esophageal hemorrhage 3 (1) 1 (0) 3 (1) 1 (0) 
Esophageal varices hemorrhage 0 (0) 1 (1) 0 (0) 1 (1) 
Gastric hemorrhage 3 (1) 3 (1) 4 (1) 1 (1) 
Hemorrhoidal hemorrhage 2 (1) 1 (0) 3 (1) 0 (0) 
Rectal hemorrhage 1 (0) 2 (0) 2 (0) 1 (0) 
Upper gastrointestinal hemorrhage 3 (0) 5 (1) 4 (1) 1 (0) 
Total 13 (3) 15 (4) 18 (5) 6 (2) 
 
Non-gastrointestinal bleeds (CTCAE grade 3–5) 
Postoperative hemorrhage 3 (3) 2 (0) 3 (3) 2 (0) 
 
Intracranial hemorrhage 5 (4) 5 (2) 5 (4) 5 (4) 
 
Hematuria 3 (0) 3 (2) 2 (2) 1 (0) 
 
Epistaxis 11 (1) 4 (0) 13 (2) 2 (0) 
Total 22 (8) 14 (4) 23 (11) 10 (4) 
     
Overall total 35 (11) 29 (9) 41 (14) 16 (6) 
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Supplementary Table 9: Details of Gastrointestinal and non-gastrointestinal bleeds by 
treatment arm 
 Treatment Arm  
SAE System / Category Low PPI High PPI Low PPI 
Asp 
High PPI 
Asp 
Total 
Gastrointestinal disorders 
Colonic hemorrhage 1 0 0 0 1 
Duodenal hemorrhage 0 0 0 2 2 
Esophageal hemorrhage 1 0 2 1 4 
Esophageal varices hemorrhage 0 1 0 0 1 
Gastric hemorrhage 1 1 2 2 6 
Hemorrhoidal hemorrhage 0 0 2 1 3 
Rectal hemorrhage 1 0 0 2 3 
Upper gastrointestinal hemorrhage 1 3 2 2 8 
Total 5 5 8 10 28 
Injury, poisoning and procedural complications 
Postoperative hemorrhage 0 2 3 0 5 
Total 0 2 3 0 5 
Nervous system disorders 
Intracranial hemorrhage 3 2 2 3 10 
Total 3 2 2 3 10 
Renal and urinary disorders 
Hematuria 3 1 0 2 6 
Total 3 1 0 2 6 
Respiratory, thoracic and mediastinal disorders 
Epistaxis 2 0 9 4 15 
Total 2 0 9 4 15 
OVERALL TOTAL 13 10 22 19 64 
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Supplementary Table 10: Primary analyses by age group 
 Number of 
patients 
Time ratio (TR) 95% CI P value 
<60 
Aspirin vs no aspirin 1264 1.22 0.82 , 1.81 0.326 
High PPI vs low PPI 1341 1.22 0.84 , 1.79 0.296 
60+ 
Aspirin vs no aspirin 1016 1.26 0.94 , 1.69 0.118 
High PPI vs low PPI 1194 1.30 0.98 , 1.71 0.064 
 
 
 
 
Supplementary Table 11: Details of numbers with LGD at baseline and newly 
diagnosed at follow up 
 Arm A Arm B Arm C Arm D Total 
LGD at baseline 31 15 11 14 71 
LGD diagnosed at 
follow up 
72 60 61 56 249 
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Supplementary table 12: Primary analyses by treatment withdrawal or completion 
 Number of 
patients 
Time ratio (TR) 95% CI P value 
Withdrawn Treatment Early 
Aspirin vs no aspirin 866 1.22 0.95 , 1.56 0.114 
High PPI vs low PPI 975 1.20 0.95 , 1.52 0.125 
Completed Treatment 
Aspirin vs no aspirin 1414 1.73 0.76 , 3.96 0.192 
High PPI vs low PPI 1560 1.11 0.51 , 2.44 0.787 
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Supplementary table 13: Cardiac Disorder Details 
Details of cardiac disorders by aspirin allocation 
Cardiac Disorder Aspirin No Aspirin 
Acute coronary syndrome 5 4 
Aortic stenosis 1  
Aortic valve disease 1 1 
Atrial fibrillation 2 4 
Atrioventricular block 
complete 
2  
Cardiac arrest 1 2 
Cardiomyopathy 2 3 
Chest pain - cardiac 5 4 
Heart failure 5 2 
Myocardial infarction 21 21 
Pericardial effusion 1 1 
Sinus bradycardia 6  
Ventricular tachycardia 1  
 53 42 
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Supplementary table 14. Primary analysis by gender 
 Number of 
patients 
Time ratio (TR) 95% CI P value 
Men 
Aspirin vs no aspirin 1,796 1.26 0.98 , 1.64 0.074 
High PPI vs low PPI 2,022 1.26 0.99 , 1.61 0.059 
Women 
Aspirin vs no aspirin 484 1.13 0.63 , 2.02 0.687 
High PPI vs low PPI 513 1.27 0.72 , 2.27 0.411 
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Supplementary table 15: Baseline of AspECT trial participants, stratified by 
randomised group 
Variable at baseline Low PPI no 
aspirin 
N=699 
High PPI no 
aspirin 
N=698 
Low PPI 
and aspirin  
N=566 
High PPI 
and aspirin 
N=572 
TOTAL 
Maximum Length of Barrett’s 
metaplasia at randomisation (cm) 
median (IQR) 
4 (3 , 6) 4 (2 , 6) 4 (3 , 6) 4 (3 , 6) 2,413 
Length of Barrett’s (stratification 
group)  
     <2cm 
     2-3cm 
     3-8cm 
     >8cm 
    Tongues 
 
 
69 (10%) 
237 (34%) 
293 (42%) 
71 (10%) 
29 (4%) 
 
 
69 (10%) 
237 (34%) 
291 (42%) 
70 (10%) 
31 (5%) 
 
 
54 (9%) 
197 (35%) 
245 (43%) 
59 (10%) 
11 (2%) 
 
 
55 (9%) 
198 (35%) 
248 (43%) 
59 (10%) 
12 (2%) 
2,535 
Age (years) 
(median (IQR)) 
59 (51 , 65) 59 (51 , 66) 58 (50 , 64) 58 (50 , 65) 2,535 
Age (stratification grouping) 
     <50 years 
     50-60 years 
     60-70 years 
     >70 years 
 
148 (21%) 
210 (30%) 
252 (36%) 
89 (13%) 
 
143 (21%) 
210 (30%) 
252 (36%) 
93 (13%) 
 
135 (24%) 
178 (31%) 
195 (35%) 
58 (10%) 
 
137 (24%) 
180 (31%) 
193 (34%) 
62 (11%) 
2,535 
Sex 
      Male 
       Female 
 
564 (81%) 
135 (19%) 
 
562 (81%) 
136 (19%) 
 
448 (79%) 
118 (21%) 
 
448 (78%) 
124 (22%) 
2,535 
Intestinal metaplasia 
(stratification group) 
      Yes 
       No 
 
 
616 (88%) 
83 (12%) 
 
 
615 (88%) 
83 (12%) 
 
 
514 (91%) 
52 (9%) 
 
 
521 (91%) 
51 (9%) 
2,535 
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Supplementary table 16: Serious adverse events CTCAE grade 3-5 by treatment arm 
 
 
 
 
 
 
 
 
 
 
 
  
System affected by serious adverse event  Arm A 
N=1265 
Arm B 
N=1270 
Arm C 
N=1142 
Arm D 
N=1138 
Serious adverse events 
Blood and lymphatic system disorders  3 4  
Cardiac disorders 29 31 28 25 
Ear and labyrinth disorders  1 1 1 
Endocrine disorders 1   1 
Eye disorders  1 1 2 
Gastrointestinal disorders 15 11 15 17 
General disorders and administration site conditions 5 5 2 6 
Hepatobiliary disorders 8 6 8 4 
Immune system disorders 1 2   
Infections and infestations 32 27 25 39 
Injury, poisoning and procedural complications 13 14 15 9 
Investigations 1  1 1 
Metabolism and nutrition disorders 2 5  2 
Musculoskeletal and connective tissue disorders 4  3 4 
Neoplasms benign, malignant and unspecified 
(including cysts and polyps) 33 34 23 18 
Nervous system disorders 16 13 15 13 
Psychiatric disorders 3 4 1 4 
Renal and urinary disorders 4 5 3 5 
Respiratory, thoracic and mediastinal disorders 3 4 5 3 
Skin and subcutaneous tissue disorders  1   
Vascular disorders 6 9 9 5 
Total 176 176 159 159 
     
Serious adverse reactions 
Related to aspirin 0 0 6 1 
Related to esomeprazole 4 4 0 2 
Related to both aspirin & esomeprazole 0 0 0 0 
Total 4 4 6 3 
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Supplementary table 17: Inclusion criteria for per protocol population 
Treatment  Therapeutic dose 
Low PPI no aspirin  
High PPI no aspirin  
1 year of esomeprazole at randomised dose  
OR  
event before 1 year and esomeprazole at randomised dose 
until the event 
 
Low PPI +  aspirin  
High PPI + aspirin  
1 year of esomeprazole at randomised dose and at least 6 
months of aspirin at randomised dose  
OR 
event before 6 months and esomeprazole and aspirin at 
randomised dose until the event  
OR  
event between 6 and 12 months and esomeprazole at 
randomised dose until the event and aspirin at randomised 
dose for at least 6 months 
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Supplementary table 18: Accelerated failure time per protocol analysis for both 
primary comparisons 
 
Number of 
patients 
Time ratio (TR) 95% CI P value 
Aspirin vs no 
aspirin 
1,812 1.25 0.96 , 1.63 0.101 
High PPI vs low 
PPI 
2,008 1.16 0.90 , 1.48 0.252 
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Supplementary figure 2: Kaplan Meier curves for comparison of Aspirin vs no Aspirin and 
high dose PPI vs low dose PPI 
2 (a). Aspirin and  HGD/Adenocarcinoma: 
 
 
2(b): Aspirin and all-cause mortality: 
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2(c) PPI and HGD/Adenocarcinoma: 
 
 
 
2 (d) PPI and all-cause mortality: 
 
 
